Avances presentes y futuros en el tratamiento del cáncer esofagogástrico

International Agency for Research on Cancer World Health Organization. The Global Cancer Observatory. [Internet]. Globocan. [Consultado julio 30 de 2023]. Disponible en: https://gco.iarc.fr/today/home

International Agency for Research on Cancer - World Health Organization. The Global Cancer Observatory 2021, Fact Sheet Colombia. [Internet]. Globocan. [Consultadojulio 30 de 2023]. Disponible en: https://gco.iarc.fr/today/data/factsheets/populations/170-colombia-fact-sheets.pdf

Situación del cáncer en la población adulta atendida en el SGSSS de Colombia, 2021 – cuenta de Alto Costo [Internet]. 2023.[Consultado julio 30 de 2023]. Disponible en: https://cuentadealtocosto.org/site/publicaciones/situacion-del-cancer-en-la-poblacion-adulta-atendida-en-el-sgsss-de-colombia-2021/

National Cancer Institute. Surveillance, Epidemiology, and End Results Program. [Internet]. Cancer Stat Facts: Esophageal cancer. [Consultado julio 30 de 2023]. Disponible en: https://seer.cancer.gov/statfacts/html/esoph.html

National Cancer Institute. Surveillance, Epidemiology, and End Results Program. [Internet]. Cancer Stat Facts: Stomach Cancer.[Consultado julio 30 de 2023]. Disponible en: https://seer.cancer.gov/statfacts/html/stomach.html

Yang WJ, Zhao HP, Yu Y, Wang JH, Guo L, Liu JY, et al. Updates on global epidemiology, risk, and prognostic factors of gastric cancer. World J Gastroenterol 2023;29(16):2452-2468. doi: 10.3748/wjg.v29. i16.2452.

Odze, R.D.; Lam, A.K.; Ochiai, A.; Washington, M.K. Tumours of the Esophagus in Digestive System Tumours. En WHO Classification of Tumours Editorial Board, 5th ed.; WHO Classification of Digestive System Tumours, IARC: Lyon, France, 2019; pp.23–58.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660.

Odze, R.D.; Lam, A.K.; Ochiai, A.; Washington, M.K. Tumours of the Stomach in Digestive System Tumours. In WHO Classification of Tumours Editorial Board, 5th ed.; WHO Classification of Digestive System Tumours, IARC: Lyon, France, 2019; pp. 59-110.

Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31 - 49. doi: 10.1111/apm.1965.64.1.31.

Obermannová R, Alsina M, Cervantes A, LEong T, Lordick F, Nilsson M, et al. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992-1004.

Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al, on behalf of the ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005-1020.

Ajani JA, D’Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(4):393-422. doi: 10.6004/ jnccn.2023.0019.

Ajani JA, D´Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Gastric cancer, Version 1.2023. [Internet]. NCCN Clinical Practice Guidelines in Oncology. [Consultado julio 30 de 2023] Disponible en: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.

Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202-209. doi: 10.1038/nature13480.

Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169-175. doi: 10.1038/nature20805.

Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449-56. doi: 10.1038/nm.3850.

Dhakras P, Uboha N, Horner V, Reinig E, Matkowskyj KA. Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma. Transl Gastroenterol Hepatol. 2020;5:55. doi: 10.21037/ tgh.2020.01.08.

Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer. Ten-Year Results of the German Gastric Cancer Study. Ann Surg. 1998;228(4):449–461.

Lerut T, Wiesel O. History of esophagectomy for cancer of the esophagus and the gastroesophageal junction. Ann Transl Med. 2021;9(10):897.

Fong ZV, Lavu H, Rosato EL, Yeo CJ, Cowan SW. Christian Albert Theodor Billroth, M.D., Founding Father of Abdominal Surgery (1829-1894). Am Surg. 2012;78(3):280–281.

Siewert JR, et al. Cardia cancer: attempt at a therapeutically relevant classification. Chirurg. 1987;58(1):25–32.

Dolan DP, Swanson SJ. The modern approach to esophagectomy-review of the shift towards minimally invasive surgery. Ann Transl Med. 2021;9(10):901. doi: 10.21037/atm.2020.03.143.

Mederos MA, de Virgilio MJ, Shenoy R, Ye L, Toste PA, Mak SS, et al. Comparison of Clinical Outcomes of Robot-Assisted, Video-Assisted, and Open Esophagectomy for Esophageal Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021;4(11):e2129228. doi: 10.1001/jamanetworkopen.2021.29228.

Davey MG, Temperley HC, O´Sullivan NJ, Vianka M, Ryan OK, Ryan EJ, et al. Minimally invasive and open gastrectomy for gastric cancer: a systematic review and network meta-anaysis of randomized clinical trials. Ann Surg Oncol. 2023;30(9):5544-5557. doi: 10.1245/s10434-023-13654-6.

Jiang J, Ye G, Wang J, Xu X, Zhang K, Wang S. The Comparison of Short- and Long-Term Outcomes for Laparoscopic Versus Open Gastrectomy for Patients With Advanced Gastric Cancer: A Meta-Analysis of Randomized Controlled Trials. Front Oncol. 2022;12:844803.

Omori T, Yamamoto K, Hara H, Shinno N, Yamamoto M, Fujita K,et al. Comparison of robotic gastrectomy and laparoscopic gastrectomy for gastric cancer: a propensity score-matched analysis. Surg Endosc. 2022;36(8):6223-6234. doi: 10.1007/s00464-022- 09125-w.

Loureiro P, Barbosa JP, Vale JF, Barbosa J. Laparoscopic Versus Robotic Gastric Cancer Surgery: Short- Term Outcomes-Systematic Review and Meta-Analy- sis of 25,521 Patients. J Laparoendosc Adv Surg Tech A. 2023;33(8):782-800. doi: 10.1089/lap.2023.0136.

Khan H, Johnston FM. Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease. J Surg Oncol. 2022;125(7):1176-1182. doi: 10.1002/jso.26894.

Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases. Ann Surg Oncol. 2020;27(6):1768-1773. doi: 10.1245/s10434-020- 08320-0.

Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309-318. doi: 10.1016/S1470- 2045(15)00553-7.

Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, et al. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO- FLOT3 Trial. JAMA Oncol. 2017;3(9):1237-1244. doi: 10.1001/jamaoncol.2017.0515.

Desiderio J, Sagnotta A, Terrenato I, Annibale B, Trastulli S, Tozzi F, et al. Gastrectomy for stage IV gastric cancer: a comparison of different treatment strategies from the SEER database. Sci Rep. 2021;11(1):7150. doi: 10.1038/s41598-021-86352-6.

Zheng C, Gao ZM, Huang HB, Li K, Liu XF. Prognostic significance of palliative gastrectomy in incurable advanced gastric cancer: a retrospective cohort study and meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(5):2299-2312. doi: 10.26355/eur- rev_202103_25262

Lin C, Fan H, Chen W, Cui L. Palliative Gastrectomy vs. Gastrojejunostomy for Advanced Gastric Cancer: A Systematic Review and Meta-Analysis. Front Surg. 2021;8:723065. doi: 10.3389/fsurg.2021.723065.

Kroese TE, van Laarhoven HWM, Nilsson M, Lordick F, Guckenberger M, Ruurda JP, D’Ugo D, Haustermans K, van Cutsem E, van Hillegersberg R, van Rossum PSN. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis. Eur J Cancer. 2022;166:254-269. doi: 10.1016/j.ejca.2022.02.018.

Montagnani F, Crivelli F, Aprile G, Vivaldi C, Pecora I, De Vivo R, et al. Long-term survival after liver metastasectomy in gastric cancer: Systematic review and meta-analysis of prognostic factors. Cancer Treat Rev. 2018;69:11-20. doi: 10.1016/j.ctrv.2018.05.010.

Aurello P, Petrucciani N, Giulitti D, Campanella L, D’Angelo F, Ramacciato G. Pulmonary metastases from gastric cancer: Is there any indication for lung metastasectomy? A systematic review. Med Oncol. 2016;33(1):9. doi: 10.1007/s12032-015-0718-4.

Yamashita K, Hosoda K, Niihara M, Hiki N. History and emerging trends in chemotherapy for gastric cancer. Ann Gastroenterol Surg. 2021;5:446-456.

Eyck BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P, et al. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J Clin Oncol. 2021;39(18):1995-2004. doi: 10.1200/JCO.20.03614.

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948-1957. doi: 10.1016/ S0140-6736(18)32557-1.

Reynolds JV, PReston SR; O´Neill B, Lowery MA, Baeksgaard L, Crosby T, et al. Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis. J Clin Oncol. 2023;41(4_suppl):295-295.

Faron M, Cheugoua-Zanetsie M, Tierney J, Thirion P, Nankivell M, Winter K, et al. MANATEC-02 Collaborative Group. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma. J Clin Oncol. 2023:JCO2202279. doi: 10.1200/JCO.22.02279. Online ahead of print.

Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: longterm follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623-1627. doi: 10.1001/ jama.281.17.1623.

Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, et al. Definitive chemo- radiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15(3):305-314. doi: 10.1016/S1470-2045(14)70028-2.

Honing J, Smit JK, Mujis CT, Burgerhof JGM, de Groot JW, Paardekooper G, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol. 2014;25:638-643.

Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389-1396. doi: 10.1016/S1470-2045(14)70473-5.

Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim KM, et al. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. J Clin Oncol. 2015;33(28):3130-3136. doi: 10.1200/JCO.2014.58.3930.

Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22(8):1081-1092.

Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, et al. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021;39(26):2903-2913. doi: 10.1200/ JCO.20.02914.

Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW):a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224-35. doi: 10.1016/S1470- 2045(14)70420-6 .

Lorenzen S, Thuss-Patience P, Pauligk C, Gökkurt E, Ettrich T, Lordick F, et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. Eur J Cancer. 2022;165:48-57. doi: 10.1016/j. ejca.2022.01.015.

Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437-1448. doi: 10.1016/S1470- 2045(18)30739-3. Erratum in: Lancet Oncol. 2018 Dec;19(12):e668. 54)

Wang J, Shi H, Yang G, Han G, Zhao M, Duan X, et al. Combined intra-arterial and intravenous chemotherapy for unresectable, advanced gastric cancer has an improved curative effect compared with intravenous chemotherapy only. Oncol Lett. 2018;15(4):5662- 5670. doi: 10.3892/ol.2018.8068.

Tang R, Chen GF, Jin K, Zhang GQ, Wu JJ, Han SG, Li B, Chao M. Efficacy of continuous gastric artery infusion chemotherapy in relieving digestive obstruction in advanced gastric cancer. World J Gastrointest Oncol. 2023;15(7):1283-1294. doi: 10.4251/wjgo. v15.i7.1283.

Martins M, Santos-Sousa H, Araújo F, Nogueiro J, Sousa-Pinto B. Impact of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer with Peritoneal Carcinomatosis: A Systematic Review and Meta-analysis. Ann Surg Oncol. 2022;29(12):7528-7537. doi: 10.1245/s10434-022-12312-7.

Prabhu A, Mishra D, Brandl A, Yonemura Y. Gastric Cancer With Peritoneal Metastasis-A Comprehensive Review of Current Intraperitoneal Treatment Modalities. Front Oncol. 2022;12:864647. doi: 10.3389/ fonc.2022.864647.

Sugarbaker PH, Van der Speeten K. Adjuvant HIPEC for gastric cancer. J Gastrointest Oncol. 2021;12(Suppl 1):S18-S19. doi: 10.21037/jgo-2020-08.

Arjona-Sánchez A, Cano-Osuna MT, Gutierrez A, Segura JJ, Perez E, Concepcion V, et al. 3140 - Adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer (HIPECT4): A randomized phase III study. Ann Oncol. 2022;33(suppl_7):S136-S196.

Casella F, Bencivenga M, Brancato G, Torroni L, Ridolfi C, Puccio C, et al. Bidirectional Approach with PIPAC and Systemic Chemotherapy for Patients with Synchronous Gastric Cancer Peritoneal Metastases (GCPM). Ann Surg Oncol. 2023;30(9):5733-5742. doi: 10.1245/s10434-023-13572-7.

Tidadini F, Abba J, Quesada JL, Baudrant M, Bonne A, Foote A, et al. Effect of Pressurized Intraperitoneal Aerosol Chemotherapy on the Survival Rate of Patients with Peritoneal Carcinomatosis of Gastric Origin. J Gastrointest Cancer. 2022;53(4):971-979. doi: 10.1007/s12029-021-00698-8.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi: 10.1016/j.cell.2011.02.013.

Yoon J, Kim TY, Oh DY. Recent Progress in Immunotherapy for Gastric Cancer. J Gastric Cancer. 2023;23(1):207-223. doi: 10.5230/jgc.2023.23.e10.

Takei S, Kawazoe A, Shitara K. The New Era of Immunotherapy in Gastric Cancer. Cancers (Basel). 2022;14(4):1054. doi: 10.3390/cancers14041054.

Yamashita, K., Iwatsuki, M., Ajani, J. A., & Baba, H. Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges. Annals of Gastroenterological Surgery.2020;4(4):369-378.

Cetin B, Wabl CA, Gumusay O. Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers. Immunotherapy. 2023;15(12):945-962. doi: 10.2217/imt-2022-0287.

Huynh J, Patel K, Gong J, Cho M, Malla M, Parikh A, Klempner S. Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials. Curr Treat Options Oncol. 202115;22(11):100. doi: 10.1007/s11864-021-00893-6.

Pietrantonio F, Randon G, Di Bartolomeo M, Luciani A, Chao J, Smyth EC, et al. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. ESMO Open. 2021;6(1):100036. doi: 10.1016/j.esmoop.2020.100036.

Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018; 24(9):1449- 1458. doi: 10.1038/s41591-018-0101-z.

Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727-730. doi: 10.1038/s41586-021-04161-3.

Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021;384(13):1191-1203. doi: 10.1056/ NEJMoa2032125. Erratum in: N Engl J Med. 2023;388(7):672.

André T, Tougeron D, Piessen G, de la Fouchardière C, Louvet C, Adenis A, et al. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clin Oncol. 2023;41(2):255-265. doi: 10.1200/JCO.22.00686.

REF: Ariga S. History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer. J Clin Med. 2023;12(10):3391. doi: 10.3390/jcm12103391.

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697. doi: 10.1016/ S0140-6736(10)61121-X. Erratum in: Lancet. 2010;376(9749):1302.

Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol. 2014;32(19):2039-2049. doi: 10.1200/ JCO.2013.53.6136

Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Siddiqui A, et al. Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial. Gastric Cancer. 2023;26(1):123-131. doi: 10.1007/s10120- 022-01335-4

Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18(5):640-653. doi: 10.1016/S1470-2045(17)30111-0.

Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020;382(25):2419-2430. doi: 10.1056/NEJ- Moa2004413.

Marusyk A, Janiszewska M, Polyak K. Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. Cancer Cell. 2020;37:471–484.

Mitani S, Kawakami H. Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance. Cancers (Basel). 2020;12(2):400. doi: 10.3390/cancers12020400.

Zhu Y, Zhu X, Wei X, Tang C, Zhang W. HER2-targeted therapies in gastric cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2021;1876(1):188549. https://doi.org/10.1016/j.bbcan.2021.188549

Hironaka S. Anti-angiogenic therapies for gastric cancer. Asia Pac J Clin Oncol. 2019;15(4):208-217. doi: 10.1111/ajco.13174)

Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012;10(17):2119-2127. doi: 10.1200/ JCO.2011.39.9824

Shen L, Li J, Xu J, Pan H, Dai G, Qin S, et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2015;18(1):168-176.

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014; 383(9911):31-39. doi: 10.1016/S0140-6736(13)61719-5

Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224-1235. doi: 10.1016/S1470- 2045(14)70420-6)

Lorenzen S, Thuss-Patience P, Pauligk C, Gökkurt E, Ettrich T, Lordick F, et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. Eur J Cancer. 2022;165:48-57. doi: 10.1016/j. ejca.2022.01.015

Lorenzen S, Thuss-Patience P, Pauligk C, Gökkurt E, Ettrich T, Lordick F, et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. Eur J Cancer. 2022;165:48-57. doi: 10.1016/j. ejca.2022.01.015

Goetze TO, Hofheinz RD, Gaiser T, Schmalenberg H, Strumberg D, Goekkurt E, et al. Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM. Int J Cancer 2023; 153(1): 153 - 163. doi: 10.1002/ijc.34495.

Satoru Iwasa, Hideaki Bando, Yongzhe Piao, Kenichi Yoshizawa, Kensei Yamaguchi. The clinical position of ramucirumab-containing regimens for advanced gastric cancer: a review of clinical trial data. Future Oncol. 2022;18(21):2709-2721.

Lam LL, Pavlakis N, Shitara K, Sjoquist KM, Martin AJ, Yip S, et al. INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG). BMC Cancer. 2023;23(1):180. doi: 10.1186/s12885- 023-10642-10647.

Kawazoe A, Fukuoka S, Nakamura Y, Kuboki Y, Wakabayashi M, Nomura S, et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Onco.l 2020;21(8):1057-1065. doi: 10.1016/S1470- 2045(20)30271-0.

Shitara K, Ben-Aharon I, Rojas C, Acosta Eyzaguirre DA, Hubert A, Araya Moya H, et al. 1223P First-line lenvatinib (Len) + pembrolizumab (Pembro) + chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in. Ann Oncol. 2022;33( Suppl_7):S1108.

Nakayama I, Takahari D. The Role of Angiogenesis Targeted Therapies in Metastatic Advanced Gastric Cancer: A Narrative Review. Journal of Clinical Medicine. 2023;12(9):3226. https://doi.org/10.3390/ jcm12093226)

Iannantuono GM, Riondino S, Sganga S, Rosenfeld R, Guerriero S, Carlucci, M., et al. NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series. Journal of Personalized Medicine. 2022;12(11):1819. https://doi.org/10.3390/jpm12111819

Garcia-Foncillas J, Bokemeyer C, Italiano A, Keating K, Paracha N, Fellous M, et al. Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers. Cancers (Basel). 2022;14(7):1793. doi: 10.3390/cancers14071793

Garralda E, Hong D, Xu R, Deeken J, Italiano A, Liu T, et al. SO-31 Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: an expanded dataset. Ann Oncol. 2022;33(Suppl_4):S370. doi 10.1016/j.annonc.2022.04.430

Hashimoto I, Oshima T. Claudins and gastric cancer: an overview. Cancers. 2022;14(2):290. doi: 10.3390/ cancers14020290

Sahin U, Türeci Ö, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLD- N18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32(5): 609-619.

Klempner SJ, Lee KW, Shitara K, Metges JP, Lonardi S, Ilson DH, et al. ILUSTRO: Phase 2 Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res. 2023;25:CCR-23-0204

105) Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655-1668. doi: 10.1016/S0140- 6736(23)00620-7

Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLD- N18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133 - 2141.

Ferguson HR, Smith MP, Francavilla C. Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling. Cell. 2021;10:1201. doi: 10.3390/cells10051201

Lengyel CG, Hussain S, Seeber A, Jamil Nidhamalddin S, Trapani D, Habeeb BS, et al. FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target? Life (Basel). 2022;12(1):81. doi: 10.3390/life12010081

Catenacci DVT, et al. FIGHT: a randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC). J Clin Oncol. 2021;39(15_suppl):4010.

Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020;382(25):2419-2430.

Gong J, Shen L, Wang W, Fang J. Safety, pharmaco- kinetics and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced sol- id cancer. J Clin Oncol. 2018;36(15_suppl):e16059. doi: 10.1200/JCO.2018.36.15_suppl.e16059

Dokter W, Ubink R, van der Lee M, van der Vleuten M, van Achterberg T, Jacobs D, et al. Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform. Mol Cancer Ther. 2014;13(11):2618–2629.

Koganemaru S, Shitara K. Antibody–drug conjugates to treat gastric cancer. Expert Opinion on Biological Therapy. 2021;21(7):923-930. doi: 10.1080/14712598.2020.1802423

Liguori L, Polcaro G, Nigro A, Conti V, Sellitto C, Perri F, et al. Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors. Pharmaceutics. 2022;14(11):2442. doi: 10.3390/pharmaceutics14112442

Antonarelli G, Giugliano F, Corti C, Repetto M, Tarantino P, Cirigliano G. Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals. 2021;14(9):884. https://doi.org/10.3390/ph14090884

Liguori L, Polcaro G, Nigro A, Conti V, Sellitto C, Perri F, et al. Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors. Pharmaceutics. 2022;14(11):2442. doi: 10.3390/pharmaceutics14112442

Liguori L, Polcaro G, Nigro A, Conti V, Sellitto C, Perri F, et al. Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors. Pharmaceutics. 2022;14(11):2442. doi: 10.3390/pharmaceutics14112442).)

Ordóñez-Reyes C, Garcia-Robledo JE, Chamorro DF, Mosquera A, Sussmann L, Ruiz-Patiño A, et al. Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question. Pharmaceutics. 2022;14(6):1243. doi: 10.3390/pharmaceutics14061243)

Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20(3):160-177. doi: 10.1038/s41571-022-00719-w

Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8(1):156. doi: 10.1038/s41392-023-01407-6

Firoz A, Ali HM, Rehman S, Rather IA. Gastric Cancer and Viruses: A Fine Line between Friend or Foe. Vaccines (Basel. 2022;10(4):600. doi: 10.3390/vaccines10040600).

Yokoda R, Nagalo BM, Arora M, Egan JB, Bogenberger JM, DeLeon TT, et al. Oncolytic virotherapy in upper gastrointestinal tract cancers. Oncolytic Virother. 2018;7:13-24. doi: 10.2147/OV.S161

Bębnowska D, Grywalska E, Pasiarski M, Góźdź S, Roliński J, Polkowski W. CAR-T Cell Therapy— An Overview of Targets in Gastric Cancer. Journal of Clinical Medicine. 2020;9(6):1894. https://doi.org/10.3390/jcm9061894

Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin 18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial interim results. Nat. Med. 2022;28:1189–1198.

Siddiqui RS, Sardar M. A systematic review of the role of chimeric antigen receptor T (CAR-T) cell therapy in the treatment of solid tumors. Cureus. 2021;13(4):e14494. doi: 10.7759/cureus.14494

Kazemi MH, Sadri M, Najafi A, Rahimi A, Baghernejadan Z, Khorramdelazad H, Falak R. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? Frontiers in Immunology. 2021;13. https://doi.org/10.3389/fimmu.2022.1018962

Solinas C, Pusole G, Demurtas L, Puzzoni M, Mascia R, Morgan G, et al.. Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. Crit Rev Oncology/ hematol. 2017;110:106–16. doi: 10.1016/j.critrevonc.2016.11.016

Chen JP, Yang J, Jiang JT, Zhuang Y, He W. Function and subsets of dendritic cells and natural killer cells were decreased in gastric cancer. Int J Clin Exp Pathol. 2014;7:8304–8311.

Du Y, Wei Y. Therapeutic Potential of Natural Killer Cells in Gastric Cancer. Frontiers in Immunology. 2019;9:422743. https://doi.org/10.3389/fimmu.2018.03095

Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, et al. CRISPR Provides Acquired Resistance against Viruses in Prokaryotes. Science. 2007;315:1709–1712. doi:10.1126/science.1138140

Jefremow A, Neurath MF, Waldner MJ. CRISPR/ Cas9 in Gastrointestinal Malignancies. Frontiers in Cell and Developmental Biology. 2021 9:727217. https://doi.org/10.3389/fcell.2021.72721

Ji YM, Zhou, XF, Zhang J, Zheng X, Li SB, Wei ZQ, et al. DEPTOR Suppresses the Progression of Esophageal Squamous Cell Carcinoma and Predicts Poor Prognosis. Oncotarget. 2016;7:14188–14198. doi:10.18632/oncotarget.7420.

Blanc V, Davidson NO. RNA Editing: Another Level of Somatic Mutagenic Activity in Gastric Cancer. Gastroenterology. 2016;151(4):584-587. doi: 10.1053/j.gastro.2016.08.044.

Wang M, Yang G, Tian Y, Zhang Q, Liu Z, Xin Y. The role of the gut microbiota in gastric cancer: the immunoregulation and immunotherapy. Front Immunol. 2023;14:1183331. doi: 10.3389/fimmu.2023.1183331.135.

Sexto RE, Al Hallak MN, Diab M, Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev. 2020;39(4):1179-1203.

Yu JI. Role of Adjuvant Radiotherapy in Gastric Cancer. J Gastric Cancer. 2023;23(1):194-206. doi: 10.5230/jgc.2023.23.e1

Teoh M, Clark CH, Wood K, Whitaker S, Nisbet A. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol. 2011;84(1007):967-996. doi: 10.1259/ bjr/22373346

Li Z, Zeng J, Wang Z, Zhu H, Wei Y. Dosimetric comparison of intensity modulated and volumetric arc radiation therapy for gastric cancer. Oncol Lett. 2014;8(4):1427-1434. doi: 10.3892/ol.2014.2363

Seyedin SN, Gannon MK, Plichta KA, Abushahin L, Berg DJ, Arshava EV, et al. Safety and Efficacy of Stereotactic Body Radiation Therapy for Locoregional Recurrences After Prior Chemoradiation for Advanced Esophageal Carcinoma. Front Oncol. 2020;10:1311. doi: 10.3389/fonc.2020.01311

Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COM- ET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051-2058. doi: 10.1016/ S0140-6736(18)32487-5.

Mahadevan A, Blanck O, Lanciano R, Peddada A, Sundararaman S, D’Ambrosio D, et al. Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry. Radiat Oncol. 2018;13(1):26. doi: 10.1186/s13014-018-0969-2

Liu Q, Zhu Z, Chen Y, Deng J, Ai D, Liu Q, et al. Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2020;108(3):707-715. doi: 10.1016/j. ijrobp.2020.05.003

Nogueira LM, Jemal A, Yabroff KR, Efstathiou JA. Assessment of proton beam therapy use among patients with newly diagnosed cancer in the US, 2004- 2018. JAMA Netw Open. 2022;5:e229025.

Collings EW, Lu L, Gupta N, Sumption MD. Accelerators, gantries, magnets and imaging systems for particle beam therapy: recent status and prospects for improvement. Front Oncol. 2022;11:737837.

Mondlane G, Gubanski M, Lind PA, Ureba A, Siegbahn A. Comparison of gastric-cancer radiotherapy performed with volumetric modulated arc therapy or single-field uniform-dose proton therapy. Acta Oncol. 2017;56:832-838.

Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, et al. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020;38(14):1569-1579. doi: 10.1200/JCO.19.02503

Mesci A, Wong RK. Current and future strategies for radiation therapy in gastric cancer. J Surg Oncol. 2022;125(7):1161-1175. doi: 10.1002/jso.26880

Favaudon V, Caplier L, Monceau V, et al. Ultrahigh doserate FLASH irradiation increases the differential response between normal and tumor tissue in mice. Sci Transl Med. 2014;6(245):245ra93

Borghini, A.; Vecoli, C.; Labate, L.; Panetta, D.; Andreassi, M.G.; Gizzi, L.A. FLASH UHDRs in radiotherapy: Preclinical and radiobiological evidence. Int. J. Radiat. Biol. 2022; 98:127–135.

Chow JCL, Ruda HE. Flash Radiotherapy: Innovative Cancer Treatment. Encyclopedia. 2023;3(3):808-823. https://doi.org/10.3390/encyclopedia3030058